Results 161 to 170 of about 3,564 (173)

Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Children Aged ≥6 Years with Cystic Fibrosis and at Least One F508del Allele: A Phase 3, Open-Label Clinical Trial

American Journal of Respiratory and Critical Care Medicine, 2023
Paul Mcnally, Jane C Davies
exaly  

Drug-drug interactions in vanzacaftor–tezacaftor–deutivacaftor versus elexacaftor–tezacaftor-ivacaftor

Pulmonary Pharmacology & Therapeutics
Esen Deniz Akman Ar, Nadir Yalcin
openaire   +2 more sources

Ivacaftor/lumacaftor/tezacaftor

Reactions Weekly, 2019
openaire   +1 more source

Elexacaftor/Ivacaftor/tezacaftor/Ivacaftor/tezacaftor

Reactions Weekly
openaire   +1 more source

Ivacaftor/tezacaftor

Reactions Weekly
openaire   +1 more source

Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial

Lancet, The, 2019
Harry Heijerman, Edward F Mckone, Damian G Downey   +2 more
exaly  

Tezacaftor and ivacaftor for the treatment of cystic fibrosis

Expert Review of Respiratory Medicine, 2020
Peter J Barry, Alex Horsley
exaly  

Elexacaftor/tezacaftor/ivacaftor

Reactions Weekly
openaire   +1 more source

Patent Review of Synthetic Routes and Crystalline Forms of the CFTR-Modulator Drugs Ivacaftor, Lumacaftor, Tezacaftor, and Elexacaftor

Organic Process Research and Development, 2019
David L Hughes
exaly  

Elexacaftor/Tezacaftor/Ivacaftor Treatment and Depression-related Events

American Journal of Respiratory and Critical Care Medicine
Bonnie Ramsey, David R Demaso, Edward Mckone   +2 more
exaly